About IDEAYA Biosciences, Inc.
https://www.ideayabio.comIDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
CEO
Yujiro S. Hata
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 142
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
BTIG
Buy
JMP Securities
Market Outperform
Mizuho
Outperform
RBC Capital
Outperform
JP Morgan
Overweight
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FMR LLC
Shares:13.15M
Value:$486.82M
BLACKROCK, INC.
Shares:8.13M
Value:$300.95M
BLACKROCK INC.
Shares:6.81M
Value:$252.09M
Summary
Showing Top 3 of 246
About IDEAYA Biosciences, Inc.
https://www.ideayabio.comIDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $207.83M ▲ | $98.35M ▲ | $119.24M ▲ | 57.37% ▲ | $1.35 ▲ | $120.27M ▲ |
| Q2-2025 | $0 | $87.57M ▲ | $-77.49M ▼ | 0% | $-0.88 ▼ | $-76.26M ▼ |
| Q1-2025 | $0 ▼ | $83.26M ▼ | $-72.18M ▲ | 0% ▲ | $-0.82 ▲ | $-71.05M ▲ |
| Q4-2024 | $7M ▲ | $150.5M ▲ | $-130.31M ▼ | -1.86K% ▼ | $-1.49 ▼ | $-129.67M ▼ |
| Q3-2024 | $0 | $65.88M | $-51.82M | 0% | $-0.6 | $-50.81M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $786.89M ▲ | $1.19B ▲ | $93.1M ▲ | $1.09B ▲ |
| Q2-2025 | $669.74M ▼ | $1.04B ▼ | $81.62M ▲ | $959.65M ▼ |
| Q1-2025 | $692.51M ▲ | $1.1B ▼ | $76.51M ▲ | $1.02B ▼ |
| Q4-2024 | $676.32M ▼ | $1.12B ▼ | $64.94M ▲ | $1.06B ▼ |
| Q3-2024 | $920.03M | $1.24B | $59.45M | $1.18B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $119.24M ▲ | $142.21M ▲ | $41.77M ▼ | $301K ▼ | $184.28M ▲ | $142.17M ▲ |
| Q2-2025 | $-77.49M ▼ | $-62.47M ▼ | $45.92M ▼ | $1.21M ▼ | $-15.35M ▼ | $-63.14M ▼ |
| Q1-2025 | $-72.18M ▲ | $-60.34M ▲ | $79.82M ▲ | $26.14M ▲ | $45.62M ▲ | $-61.67M ▲ |
| Q4-2024 | $-130.31M ▼ | $-121.66M ▼ | $-197.11M ▼ | $2.75M ▼ | $-316.01M ▼ | $-122.76M ▼ |
| Q3-2024 | $-51.82M | $-49.23M | $-20.04M | $286.5M | $217.23M | $-49.69M |
Revenue by Products
| Product | Q1-2023 | Q2-2023 | Q3-2023 | Q3-2025 |
|---|---|---|---|---|
 Research and Development Services | $0 ▲ | $0 ▲ | $0 ▲ | $140.00M ▲ |
 Werner Helicase Program Research And Development Service | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Yujiro S. Hata
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 142
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
BTIG
Buy
JMP Securities
Market Outperform
Mizuho
Outperform
RBC Capital
Outperform
JP Morgan
Overweight
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FMR LLC
Shares:13.15M
Value:$486.82M
BLACKROCK, INC.
Shares:8.13M
Value:$300.95M
BLACKROCK INC.
Shares:6.81M
Value:$252.09M
Summary
Showing Top 3 of 246